A Mid-Year Look at 80 Chinese IVD Companies’ H1 Financial Reports Section 3

Profitability

Table of Net Profits for Leading IVD Companies in 2025 H1

*The above table is sorted by net profit attributable to shareholders of the parent company in descending order.

Profitability among IVD companies diverged sharply. Mindray led with a net profit of RMB 5.069 billion in H1 2025, followed by Andon Health (RMB 920 million) and Snibe (RMB 771 million). Only four companies—Novogene, Sansure Biotech, AmoyDx, and Alltest—achieved both revenue and net profit growth. Some, like Improve Medical, posted striking net profit growth (389.4%), but most companies saw shrinking margins or losses. The divergence reflects post-pandemic demand declines, intensified competition, and rising costs, which have widened the gap between leading players and smaller firms.

Table of Net Profits for IVD-Related Companies in 2025 H1

*The above table is sorted by net profit attributable to shareholders of the parent company in descending order.

For IVD-related firms, Fosun Pharma led with RMB 1.702 billion net profit, followed by Livzon (RMB 1.282 billion). Five companies, including ACRO Biosystems, Nanomicro Technology, Contec Medical, Bioeasy Biotechnology, and GenScript Biotech, saw net profit growth above 40%. Notably, Bioeasy Biotechnology achieved a 250% profit surge, driven by overseas expansion and a RMB 600 million global procurement deal with Denmark’s Novonesis. Contec Medical’s profit more than doubled (+107%), boosted by soaring demand in Southeast Asia, the Middle East, and Eastern Europe. GenScript’s growth (+85.46%) came from its booming CDMO business (+511%), as well as higher Carvykti sales (USD 808 million), narrowing losses and strengthening profitability.

Last: A Mid-Year Look at 80 Chinese IVD Companies’ H1 Financial Reports Section 2